Penn Medicine News Blog
When cancer runs in the family, genetic testing can help with identification and disease management. Kimyatta (left) with her aunt, mother, grandfather and grandmother.
After Ashley Dedmon's mother passed away from metastatic breast cancer, she discovered the disease had impacted three generations of women in her family. Ashley shares her journey and how working with the Basser Center for the Black and BRCA Initiative has helped her spread awareness in educating younger generations.
Dana Clark, MS, Basser Center genetic counselor, spoke about the value of genetic testing in cancer prevention, while dispelling myths associated with access and cost. Her patient, Kimyatta, shares her story and strong hereditary link to the disease.
Precision Oncology News
Susan Domchek, MD, Executive Director of the Basser Center, presented on a clinical trial assessing if a vaccine can prevent breast cancer patients with BRCA1/2 mutations from relapsing and prevent healthy people with mutations from developing cancer.
Robert H. Vonderheide, MD, DPhil, Director of the Abramson Cancer Center, and team are studying immune responses to a vaccine with patients in remission from BRCA-related cancers. Next phase: 28 healthy people with BRCA mutations will receive the vaccine.
For Hispanic Heritage Month, ELLE Magazine spoke with Basser Center Executive Director Susan Domchek and Penn Medicine’s Dr. Carmen Guerra about the ways Basser and the Abramson Cancer Center are leading the charge to provide life-saving cancer screening tests for minority women—and Latinas in particular.
Basser Executive Director Susan Domchek, MD, shares that genetic testing for hereditary cancer should be offered to all women aged older than 65 years with triple-negative or ER-negative breast cancer, according to results from a study published in the Journal of Clinical Oncology.
New York Times
A growing number of cancer patients, including those with breast cancer, are being spared chemotherapy treatment in favor of other options. Basser Executive Director Susan Domchek, MD, was featured in an article about the use of more precise treatments.
University of Penn
A new scholarship at the Perelman School of Medicine, funded by members of the Advisory Board of Penn Medicine's Basser Center for BRCA, paves the way for greater diversity in the field of genetic counseling.
A new study from Penn Medicine and the Basser Center finds Black and white women have the same gene mutations linked to breast cancer risk. The findings challenge past, smaller studies that found Black women face a greater genetic risk.
Very Well Health
Basser Young Leadership Council co-founder Erika Stallings shares the story of her BRCA journey with Very Well Health.
A recently published JAMA Network study evaluated the use of polygenic risk scores (PRSs) models in a clinical setting for breast cancer risk among women of European, African, and Latinx ancestry.
Penn Medicine News
A meta-analysis of nearly 200,000 men revealed 22 new genetic locations that could be susceptible to inherited testicular germ cell tumors (TGCT) — a 40 percent increase in the number of regions known to be associated with the cancer. The multi-institutional meta-analysis was led by Basser Director of Genetics, Katherine L. Nathanson, MD.
Penn Medicine News
The prevalence of genetic mutations associated with breast cancer in Black and white women is the same, according to a new JAMA Oncology study of nearly 30,000 patients led by Basser Center researchers. “The findings challenge past, smaller studies that found Black women face a greater genetic risk and the suggestion that race should be an independent factor when considering genetic testing,” said first author Susan Domchek, MD, Basser Execute Director.
Basser Executive Director Susan Domchek, MD, received a Fellow of the American Society of Clinical Oncology distinction at the American Society of Clinical Oncology annual meeting. The honor recognizes ASCO members’ extraordinary volunteer service, dedication, and commitment to the society.
Findings to be presented during a plenary session at the American Society of Clinical Oncology meeting show that a PARP inhibitor significantly reduced the risk that breast cancer would return when given to patients with the BRCA mutation. Basser Executive Director Susan Domchek, MD, serves as lead investigator of the Penn trial.
Susan Domchek, MD, Basser Executive Director, was featured in a story about Latinas and BRCA mutations. Despite the high prevalence of the mutations, awareness of hereditary cancer risks and genetic testing is low among this group, limiting their options for early treatment, she said.
Penn Medicine News
Many pancreatic cancer patients with BRCA and PALB2 mutations saw their tumors stop growing or shrink substantially after being switched from chemotherapy to the PARP inhibitor rucaparib, according to results from a clinical trial led by Basser Center researchers.